



12TH AIS 2024

JUNE 20-21 2024
MONTPELLIER, FRANCE

Post-Event Report

OUR STORY

In order to provide to the scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry the LabEx MAbImprove started the **Antibody Industrial Symposium** in 2013.

Here are the previous editions:

1st Antibody Industrial Symposium (AIS2013) - May 28 in Tours, 2013 - *“Antibody Biosimilars”*

2nd Antibody Industrial Symposium (AIS2014) – July 3 in Montpellier, 2014 - *“MABDosing”*

3rd Antibody Industrial Symposium (AIS2015) – July 2 in Tours, 2015 - *“MABDelivery”*

4th Antibody Industrial Symposium (AIS2016) – July 4-5 in Montpellier, 2016 - *“Current and Next Generation Antibody Formats”*

5th Antibody Industrial Symposium (AIS2017) – June 27-28 in Tours, 2017
“ADCs – Design & Development for Therapy and Imaging in and beyond Cancer”

6th Antibody Industrial Symposium (AIS2018) – June 25-26 in Montpellier, 2018
“TARGETS FOR MABS: Innovative Approaches for their Discovery & Validation”

7th Antibody Industrial Symposium (AIS2019) – June 24-25 in Tours, 2019
“Harnessing the Immune System with Therapeutic Antibodies”

8th Antibody Industrial Symposium (AIS2020) – November 23-24 2020, Virtual format
“Multispecific Antibodies, Ab-like Molecules & Adoptive Cell Therapy for Fighting Diseases”

9th AIS (AIS2021) – June 22-25 2021, Virtual format

10th AIS(AIS2022) – June 28-29 in Montpellier, 2022 – **ANNIVERSARY EDITION**

11th AIS(AIS2023) – June 22-23 in Tours, 2022 – *Parallel Tracks on therapeutic Abs and Cell & Gene Therapy*

12th AIS(AIS2024) – June 20-21 in Montpellier, 2024 – *Next generation of Abs & New modalities*

SAVE THE DATE



Since the 4th edition of AIS2016, MabDesign has joined forces in the organization of this congress, bridging academia and industry. Since 12 years, the AIS has allowed to gather more than **3730+ Participants** from **23 different countries**, **487+ Expert Speakers**, held **3160+ B2B meetings**, presented **106 Pitches**, **289+ posters** and **283 Exhibitors/Sponsors** showcase their latest innovations, in the field of therapeutic antibodies, recombinant proteins and other biotherapeutics research and development.

KEY FIGURES



12th AIS Congress

JUNE 20-21 2024
Montpellier, FRANCE



450 Participants



450 B2B Meetings



44 Sponsors/Exhibitors



60 Speakers



58 Posters



20 Countries

KEY FIGURES


- ✓ **450+** participants from 23 different countries

✓ **450+** BtoB meetings took place


✓ **226+** different organizations present
- ✓ **44** Exhibitors and Sponsors

✓ **60** High-profile Speakers

✓ **58** Poster presentations



WHERE FROM?



2024 SPONSORS & EXHIBITORS

WITH THE SUPPORT OF









2024 INSTITUTIONAL & MEDIA PARTNERS

THE 2024 AGENDA

DAY 1

Thursday, June 20th 2024

8h00 Registration and welcome coffee

8h45 Welcome Address - Einstein Auditorium

9h00 **OPENING KEYNOTE LECTURES** - Einstein Auditorium

Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy



Christian Klein

Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich
Roche pRED, Switzerland

Clinical development of bispecific antibodies and ADCs: toxicity mitigation and activity optimization strategies in expanded phase I trials



Elisa Fontana

MD, PhD, Hospital Medical Director
The Sarah Cannon Research Institute in London, UK

10h00 Coffee Break at Exhibition Hall

10h30 **Paving the way for the next-generation of Antibodies & New Modalities**

- Einstein Auditorium

Session I

KnotBodies: creating Ion Channel Modulating Antibodies by fusing Knottins in Antibody loops



Pedro Villar

Senior Scientist
Maxion Therapeutics, UK

From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology



Paula Videira

Co-founder and CTO

CellmAbs

Associate Professor and Group Leader

UCIBIO, NOVA School of Science and Technology, NOVA University Lisbon, Portugal

Optimizing Discovery Strategies for TCR Bispecifics



Peter Molloy

Senior Fellow, Protein Engineering

Immunocore Ltd, UK

Antibody-based Cancer Therapies : latest developments

- Barthez Auditorium

Bispecific Antibody Drug Conjugates (BsADCs): strategies and challenges



Alain Beck

Senior Director, Biologics CMC & developability

Pierre Fabre, France

Innovative cancer therapies based on first-in-class antibodies anti-GPCR drug conjugates



Aïphi Andrée Nguyen

CEO

Skymab Biotherapeutics, France

Merus Class of Bispecific ADC (ADClonics™) to Achieve Improved Binding Selectivity, Internalization and Tumor Cell Killing



Peter Lowe

Director Antibody Engineering

Merus, Netherlands

THE 2024 AGENDA

Leveraging cutting-edge DNA technologies to build precision libraries for antibody engineering



Radha Parmar

Science & Technology Consultant, Biologics - EMA

Twist Bioscience, USA

Comprehensive and Reliable Characterization of Antibody Therapeutics thanks to Kimialys's innovative SPR biochips



Claude Nogues

CSO & Co-founder

Kimialys, France

12h10

Lunch at Exhibition Hall

13h00

Workshop : How to analyze NGS antibody sequence data in PipeBio - Barthez Auditorium



Simit Patel

Senior Field Applications Scientist

PipeBio, Denmark

14h00

Paving the way for the next-generation of Antibodies & New Modalities

- Einstein Auditorium

Session II

Exploiting the advances of soloMER biologics to deliver multi-functional products for autoimmune diseases and cancer




Caroline Barelle

CEO & founder

Elasmogen, UK

De novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization



Stefan Zielonka

Global Head of Antibody Discovery & Protein Engineering

Merck Healthcare KGaA

Professor of Biomolecular Immunotherapy

Technical University of Darmstadt, Germany

Avidity Engineering : a next frontier in the development of differentiating antibody therapeutics



Simone Oostindie

Director Research & Discovery

GYES, Netherlands

Targeting tumor microenvironment with human antibodies demonstrating improved developability properties



Anne Chevrel

Head of Discovery

Mabqi, France

Discovery and Development on Non-IgG based antibodies treatments

- Barthez Auditorium

Using IgE based antibodies to treat cancer



Elizabeth Hardaker

VP of Biology

Epsilon, UK

Engineered monoclonal IgA for the treatment of cancer




Mitchell Evers

Antibody Scientist

Utrecht University, Netherlands

Streamlining Therapeutic Antibody Development with a Homogeneous Bioluminescent Immunoassay for Signaling Pathway Analysis



Hicham Zegzouti

Senior Research Scientist - Group Leader

Promega, USA

Low-volume, automation friendly protein characterization



Sandra Flores

Field Applications Scientist

Unchained Labs, Germany

THE 2024 AGENDA

15h40

Coffee Break at Exhibition Hall

16h00

Pitch Session : Innovative Approaches and New trend Technologies

- Einstein Auditorium

Session II

Assessing the immunomodulatory effects of Immune Checkpoint Antibodies using 3D cell co-culture models



Marcin Krzykawski
CEO
Real Research, Poland

Generation of nano-antibodies using extracellular vesicles for diagnostic purposes



Clara Bouyx

Post-Doc CNRS (Operations manager of the LabCom NVDIAG)
Laboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), France

APL-1030, a Novel High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation



Mathieu Cinier
CSO
Affilogic, France

A new technology for lysosomal targeted degradation of extracellular and membrane proteins: antibody engineering with mannose 6-phosphate analogues



'Ivona' Božić
R&D manager
NanoMedSyn, France

Tumor associated macrophages targeting with a new specific monoclonal antibody



Mary Poupot

Researcher

Centre de Recherche en Cancérologie de Toulouse, Inserm, France

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer




Emmanuelle Liaudet-Coopman

Senior Scientist, DR2

Institut de Recherche en Cancérologie de Montpellier (IRCM)
Inserm U1194
Université Montpellier
Institut Régional du Cancer de Montpellier (ICM), France

Workshop ENOTTA - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA): Assembling a Multidisciplinary Puzzle

- Barthez Auditorium



Olga Pitsillidou

Officer in the Pharmaceutical Care Team

Health Insurance Organization Cyprus (HIO) & University of Groningen



Azra Guzonjić

Teaching Assistant

University of Belgrade, Serbia



Ana Homšek

Teaching Assistant

University of Belgrade, Serbia



Georgios Kararigas

Professor

University of Iceland, Iceland

THE 2024 AGENDA

Involvement of tumor microenvironment during targeted radionuclide therapy



Timothée David

Post-doctoral Researcher

Institut de Recherche en Cancérologie de Montpellier (IRCM)
InsERM U1194, France

Leveraging Photonic Integrated Circuit (PIC) technology to advance label-free biosensing for antibody screening and Point of Care diagnostics



Joël van der Vegt

Business Development Specialist

Delta Life Science, The Netherlands

Epitope mapping case studies by Deep Mutational Scanning



Raphael Sierocki

CEO/CSO

Deeptope, France

17h30 • Round table - Enhancing Investment Understanding - Einstein Auditorium



Maxence de Vienne

Partner

Elyan



Lorenzo Pompei

General Delegate

Angels Santé



Adrien Clavairolly

Senior Associate

AdBio Partners

18h20 • Investor's Pitch - Private session - Barthez Auditorium

19h00 • Poster Presentation - Dinner Cocktail Reception at Exhibition Hall

20h30 • Announcement of « BEST POSTER » by Biothérapie Innovation Occitanie



21h00 • End of DAY 1

DAY 2

Friday, June 21st 2024

8h00 Welcome coffee

8h30 Efficacy and safety from preclinical to FIH trials

- Einstein Auditorium

Session I

Feasibility Assessment in Therapeutic Antibody Development: Leveraging PK/PD Modeling to Navigate Challenges and Mitigate Pitfalls



Lionel Renaud

PK/PD and Systems Pharmacology modeler

Lyo-X, Switzerland

From preclinical to clinical: PK-PD modelling of an antibody drug conjugate for therapeutic index prediction



Laurence del Frari

Pharmacokineticist, Modeling & Simulation

Pierre Fabre, France

Pharmacokinetics strategies to support First in Human studies for different biotherapeutic modalities



Antoine Deslandes

Global Head of Pharmacokinetics for Devices & Biotherapeutics

SANOFI, France

10h00 Coffee Break at Exhibition Hall

10h30 Efficacy and safety from preclinical to FIH trials

- Einstein Auditorium

Session II

Case study on Clinical Dose Selection for TIGIT monospecific and bispecific antibodies



Pierre Ferre

VP Preclinical Development

Compugen Ltd, Israel

From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology



Alex Phipps

Senior Director, Global Clinical Development, AstraZeneca

Non-oncology diseases/next generation of immunotherapies

- Barthez Auditorium

The role of broadly neutralizing antibodies in HIV cure strategies



Ole Søgaard

Professor

Institut for Klinisk Medicin, Aarhus University, Denmark

Multimeric complexes to unlock the therapeutic potential of innate immunity



Carole Seguin-Devaux

Head of Research Unit

Luxemburg Institut of Health, Luxembourg

Antibody-based and CAR-T cell-based therapeutic approaches against SARS-CoV2 infections



Mireia Pelegrin

DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherapy group

IRM-INSERM U1183-CHU Saint Eloi, France

AI and Machine Learning for Antibody discovery and Optimization

- Barthez Auditorium

Computational Approaches to Antibody Optimization and Humanization



Pietro Sormani

Group Leader, Royal Society Univ. Research Fellow

University of Cambridge, UK

Towards an Integrated Platform for Antibody Discovery



Alex Phipps

Executive Director, Head of Clinical Pharmacology and Quantitative Pharmacology (CPQP) - Oncology
AstraZeneca, UK

Next Generation Accelerated GMP Quality Control from Master Cell Banks to Drug Substance release testing



Philippe Grimm

Business Development & Marketing Director
SGS Vitrology, UK

Screening&Fluidics, a droplet microfluidics service provider for the discovery of your biological agent



Georges Gaudriault

CEO
Screening & Fluidics, France

Novel PK Bioanalytical Approach Using a 1.5 plex Hybrid LC-MS/MS Assay for Quantification of Total Drug (ADC/ARC) and Total Ab for Support of Non-clinical and Clinical Trials



Dawn Dufield
Scientific Officer
KCAS Bio, USA

Andrew Phillips

Head of Biologics AI Platform
SANDOZ, UK

Unlocking the potential of artificial intelligence in antibody discovery



Thomas Bourquard
CSO and co-founder
MabSilico, France

12h00

Lunch at Exhibition Hall

13h00

Round Table "Nourrir l'innovation : Attirer et recruter les meilleurs talents dans l'industrie du Biomédicament"

- Barthez Auditorium



14h00

Advancing new Antibodies approaches into the Clinic

- Einstein Auditorium

First-in-Class anti-ChemR23 pro-resolutive agonist mAbs triggers the Resolution of chronic Inflammation



Nicolas Poirier

CEO
Ose Immunotherapeutics, France

Next-generation bispecific T cell engagers with built-in autoregulation to prevent treatment-related adverse events in adoptive T cell immunotherapies



Innovative Approaches to overcome Bioprocessing Challenges

- Barthez Auditorium

Therapeutic Protein Charge Variant Characterization with Intact Mass and Peptide Mapping Following Microgram Preparative Capillary Isoelectric Focusing Electrophoresis Fractionation



G ry Van Vyncht
Scientific Director
Quality Assistance, Belgium

Industrialization of biotechnology process with continuous DSP approach



David Balbuena
Director of Business Development
LFB Biomanufacturing, France

THE 2024 AGENDA

Vincent Muczynski
Director of Biology
Novagen Ltd
Research Fellow
University College London - Cancer Institut, UK

From Bench to Bedside : glenzocimab journey into the clinic




Elie Toledano
Head of Scientific Affairs and Business Intelligence
Acticor Biotech, France

Accelerating drug discovery using advanced antibody development platforms



Yu-Chih Lin
PhD. Technical specialist
Sino Biological, Germany

Smart Technologies and Smart Processes to serve Downstream Process Intensification Levels



Fabien Rousset
Principal Expert - Chromatography / DSP, BPS - Separation Technologies
SARTORIUS, France

Synthetic Biology tools to accelerate antibody development



Tatiana Konovalova
Bioinformatics R&D manager
Thermo Fisher Scientific, Germany

15h40 • **Closing Keynote** - Einstein Auditorium

Bispecific Antibodies against infectious diseases



Luca Varani
Structural Biology Group Leader
Institute for Research in Biomedicine, Switzerland

16h10 • Announcement of AIS2025

16h30 • End of Congress

THE 2024 WORKSHOPS

WORKSHOP by PipeBio

How to analyze NGS antibody sequence data in PipeBio

June 20th 2024 at 13h00 in Barthez Auditorium

The PipeBio bioinformatics platform makes the analysis of large NGS and Sanger sequencing datasets fast and easy, enabling researchers to find high quality sequence candidates for antibodies and related molecules.

In this workshop, we will re-analyze a public NGS dataset and walk through the steps in detail. You will learn about QC, sequence annotation, clustering, comparison, sequence prioritization, visualization, integration with assay data, hit-picking and more.



Given by Simit Patel

Senior Field Applications Scientist

PipeBio, Denmark

WORKSHOP by



European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA): Assembling a Multidisciplinary Puzzle

June 20th 2024 at 16h00 in Barthez Auditorium

Speakers :



Olga Pitsillidou

Officer in the Pharmaceutical Care Team

Health Insurance Organization Cyprus (HIO) & University of Groningen



University of Belgrade



Azra Guzonjić

Teaching Assistant

University of Belgrade, Serbia



University of Belgrade



Ana Homšek

Teaching Assistant

University of Belgrade, Serbia



Georgios Kararigas

Professor

University of Iceland, Iceland

Atelier par



Nourrir l'innovation : Attirer et recruter les meilleurs talents dans l'industrie du Biomédicament

June 21st 2024 at 13h00 in Barthez Auditorium

Au cours de cet atelier, les tendances actuelles et les défis du recrutement pour le secteur de la santé seront abordés, suivi d'une discussion sur des idées et bonnes pratiques, étayée par des exemples, des témoignages et des Q/R.

Animateurs :



Muriel Fossati

Manager Life Science, Réseau Experts & Cadres

Manpower Life Science



Clément Fayard

Réseau Experts & Cadres, Responsable d'agence

Manpower Life Science



Floriane Lacour

Responsable du Pôle Relations Entreprises, Partenariats et Recrutement

Association Bernard Gregory

2024 SCIENTIFIC ADVISORY BOARD



Alain Beck

Senior Director, Biologics CMC & developability
Centre d'immunologie Pierre Fabre



Thierry Wurch

Senior Director, Global External Innovation and Partnering in Oncology
Evotec




Ana Antunes

Head of Scientific Events and Communication
MabDesign




Nicolas Poirier

Chief Executive Officer
OSE Immunotherapeutics



Lennart Zabeau

Principal Scientist
Orionis Biosciences, Belgium



Stéphanie Cornen

Head of Corporate Development
Innate Pharma



Francis Duffieux

Principal Scientist, Head of Protein Purification, LMR Vitry
SANOFI



Mireia Pelegrin

DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherapy group
U1183-IRMB, Montpellier, France



Mar Naranjo Gomez

CNRCN-Inserm, Antibodies, Immunomodulation and Immunotherapy
U1183-IRMB, Montpellier, France



Bruno Robert

CR, Equipe Criblage fonctionnel et ciblage du cancer
IRCM, INSERM U1194, Montpellier, France



Pierre Ferré

VP Preclinical Development
Compugen Ltd., Israel



Virginie Lafont

Senior Scientist
IRCM, INSERM U1194, Montpellier, France



Marie-Alix Poul

Professor of Immunology
UM, Montpellier, France



Peter Lowe

Director Antibody Engineering
Merus, Netherlands



Fabien Rousset

Principal Expert - Chromatography / DSP, BPS - Separation Technologies
SARTORIUS



Join us in 2025



2nd Innovations for Cell and Gene Therapies Congress (ICGT2025)

22-23 May 2025 in SANOFI Campus Gentilly, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr



13th Antibody Industrial Symposium (AIS2025)

25-26 June 2025 in Tours, France

Ana Antunes

+33 (0)7 59 56 52 76

ana-sofia.antunes@mabdesign.fr



10th Bioproduction Congress (BIOPC2025)

22-23 September 2025 in Lyon, France

Pierre-Mehdi Hammoudi

+33 (0)4 78 02 39 89

pierre-mehdi.hammoudi@mabdesign.fr



9th Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2025)

November 2025 in Lyon, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr